Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

1. Garcia-Sanz, R.
2. Sureda, A.
3. De La Cruz, F.
4. Canales, M.
5. Gonzalez, A.P.
6. Pinana, J.L.
7. Rodriguez, A.
8. Gutierrez, A.
9. Domingo-Domenech, E.
10. Sanchez-Gonzalez, B.
11. Rodriguez, G.
12. Lopez, J.
13. Moreno, M.
14. Rodriguez-Salazar, M.J.
15. Jimenez-Cabrera, S.
16. Caballero, M.D.
17. Martinez, C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDZ009 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus